Translocations involving anaplastic lymphoma kinase (ALK)

Justus Duyster, Renyuan Bai, Stephan W. Morris

Research output: Contribution to journalArticle

Abstract

Anaplastic large-cell lymphoma (ALCL) comprises a group of non-Hodgkin's lymphomas (NHLs) that were first described in 1985 by Stein and co-workers and are characterized by the expression of the CD30/Ki-1 antigen (Stein et al., 1985). Approximately half of these lymphomas are associated with a typical chromosomal translocation, t(2;5)(p23;q35). Much confusion about the exact classification and clinicopathological features of this subgroup of NHL was clarified with the identification of NPM-ALK (nucleophosmin-anaplastic lymphoma kinase) as the oncogene created by the t(2;5) (Morris et al., 1994). With the discovery of NPM-ALK as the specific lymphoma gene mutation, this NHL subtype could be redefined on the molecular level. This achievement was enhanced by the availability of specific antibodies that recognize ALK fusion proteins in paraffin-embedded lymphoma tissues. Several excellent recent renews have summarized the histopathological and molecular findings of ALCL and their use in the classification of this lymphoma entity (Anagnostopoulos and Stein, 2000; Benharroch et al., 1998; Drexler et al., 2000; Foss et al., 2000; Gogusev and Nezelof, 1998; Kadin and Morris, 1998; Ladanyi, 1997; Morris et al., 2001; Shiota and Mori, 1996; Skinnider et al., 1999; Stein et al., 2000). This review will focus on the molecular function and signal transduction pathways activated by ALK fusion oncogenes, with recent advances and possible clinical implications to be discussed.

Original languageEnglish (US)
Pages (from-to)5623-5637
Number of pages15
JournalOncogene
Volume20
Issue number40 REV. ISS. 4
DOIs
StatePublished - Sep 10 2001
Externally publishedYes

Fingerprint

Lymphoma
Non-Hodgkin's Lymphoma
Anaplastic Large-Cell Lymphoma
Oncogene Fusion
CD30 Antigens
Morus
Genetic Translocation
Oncogenes
Paraffin
Signal Transduction
Mutation
anaplastic lymphoma kinase
Antibodies
Genes
Proteins
nucleophosmin

Keywords

  • ALCL
  • ALK
  • IMT
  • NPM-ALK
  • Pleiotrophin
  • Variant ALK fusions

ASJC Scopus subject areas

  • Molecular Biology
  • Cancer Research
  • Genetics

Cite this

Translocations involving anaplastic lymphoma kinase (ALK). / Duyster, Justus; Bai, Renyuan; Morris, Stephan W.

In: Oncogene, Vol. 20, No. 40 REV. ISS. 4, 10.09.2001, p. 5623-5637.

Research output: Contribution to journalArticle

Duyster, J, Bai, R & Morris, SW 2001, 'Translocations involving anaplastic lymphoma kinase (ALK)', Oncogene, vol. 20, no. 40 REV. ISS. 4, pp. 5623-5637. https://doi.org/10.1038/sj.onc.1204594
Duyster, Justus ; Bai, Renyuan ; Morris, Stephan W. / Translocations involving anaplastic lymphoma kinase (ALK). In: Oncogene. 2001 ; Vol. 20, No. 40 REV. ISS. 4. pp. 5623-5637.
@article{24f7e00fede84c4a965e6521ee1dff02,
title = "Translocations involving anaplastic lymphoma kinase (ALK)",
abstract = "Anaplastic large-cell lymphoma (ALCL) comprises a group of non-Hodgkin's lymphomas (NHLs) that were first described in 1985 by Stein and co-workers and are characterized by the expression of the CD30/Ki-1 antigen (Stein et al., 1985). Approximately half of these lymphomas are associated with a typical chromosomal translocation, t(2;5)(p23;q35). Much confusion about the exact classification and clinicopathological features of this subgroup of NHL was clarified with the identification of NPM-ALK (nucleophosmin-anaplastic lymphoma kinase) as the oncogene created by the t(2;5) (Morris et al., 1994). With the discovery of NPM-ALK as the specific lymphoma gene mutation, this NHL subtype could be redefined on the molecular level. This achievement was enhanced by the availability of specific antibodies that recognize ALK fusion proteins in paraffin-embedded lymphoma tissues. Several excellent recent renews have summarized the histopathological and molecular findings of ALCL and their use in the classification of this lymphoma entity (Anagnostopoulos and Stein, 2000; Benharroch et al., 1998; Drexler et al., 2000; Foss et al., 2000; Gogusev and Nezelof, 1998; Kadin and Morris, 1998; Ladanyi, 1997; Morris et al., 2001; Shiota and Mori, 1996; Skinnider et al., 1999; Stein et al., 2000). This review will focus on the molecular function and signal transduction pathways activated by ALK fusion oncogenes, with recent advances and possible clinical implications to be discussed.",
keywords = "ALCL, ALK, IMT, NPM-ALK, Pleiotrophin, Variant ALK fusions",
author = "Justus Duyster and Renyuan Bai and Morris, {Stephan W.}",
year = "2001",
month = "9",
day = "10",
doi = "10.1038/sj.onc.1204594",
language = "English (US)",
volume = "20",
pages = "5623--5637",
journal = "Oncogene",
issn = "0950-9232",
publisher = "Nature Publishing Group",
number = "40 REV. ISS. 4",

}

TY - JOUR

T1 - Translocations involving anaplastic lymphoma kinase (ALK)

AU - Duyster, Justus

AU - Bai, Renyuan

AU - Morris, Stephan W.

PY - 2001/9/10

Y1 - 2001/9/10

N2 - Anaplastic large-cell lymphoma (ALCL) comprises a group of non-Hodgkin's lymphomas (NHLs) that were first described in 1985 by Stein and co-workers and are characterized by the expression of the CD30/Ki-1 antigen (Stein et al., 1985). Approximately half of these lymphomas are associated with a typical chromosomal translocation, t(2;5)(p23;q35). Much confusion about the exact classification and clinicopathological features of this subgroup of NHL was clarified with the identification of NPM-ALK (nucleophosmin-anaplastic lymphoma kinase) as the oncogene created by the t(2;5) (Morris et al., 1994). With the discovery of NPM-ALK as the specific lymphoma gene mutation, this NHL subtype could be redefined on the molecular level. This achievement was enhanced by the availability of specific antibodies that recognize ALK fusion proteins in paraffin-embedded lymphoma tissues. Several excellent recent renews have summarized the histopathological and molecular findings of ALCL and their use in the classification of this lymphoma entity (Anagnostopoulos and Stein, 2000; Benharroch et al., 1998; Drexler et al., 2000; Foss et al., 2000; Gogusev and Nezelof, 1998; Kadin and Morris, 1998; Ladanyi, 1997; Morris et al., 2001; Shiota and Mori, 1996; Skinnider et al., 1999; Stein et al., 2000). This review will focus on the molecular function and signal transduction pathways activated by ALK fusion oncogenes, with recent advances and possible clinical implications to be discussed.

AB - Anaplastic large-cell lymphoma (ALCL) comprises a group of non-Hodgkin's lymphomas (NHLs) that were first described in 1985 by Stein and co-workers and are characterized by the expression of the CD30/Ki-1 antigen (Stein et al., 1985). Approximately half of these lymphomas are associated with a typical chromosomal translocation, t(2;5)(p23;q35). Much confusion about the exact classification and clinicopathological features of this subgroup of NHL was clarified with the identification of NPM-ALK (nucleophosmin-anaplastic lymphoma kinase) as the oncogene created by the t(2;5) (Morris et al., 1994). With the discovery of NPM-ALK as the specific lymphoma gene mutation, this NHL subtype could be redefined on the molecular level. This achievement was enhanced by the availability of specific antibodies that recognize ALK fusion proteins in paraffin-embedded lymphoma tissues. Several excellent recent renews have summarized the histopathological and molecular findings of ALCL and their use in the classification of this lymphoma entity (Anagnostopoulos and Stein, 2000; Benharroch et al., 1998; Drexler et al., 2000; Foss et al., 2000; Gogusev and Nezelof, 1998; Kadin and Morris, 1998; Ladanyi, 1997; Morris et al., 2001; Shiota and Mori, 1996; Skinnider et al., 1999; Stein et al., 2000). This review will focus on the molecular function and signal transduction pathways activated by ALK fusion oncogenes, with recent advances and possible clinical implications to be discussed.

KW - ALCL

KW - ALK

KW - IMT

KW - NPM-ALK

KW - Pleiotrophin

KW - Variant ALK fusions

UR - http://www.scopus.com/inward/record.url?scp=0035839867&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0035839867&partnerID=8YFLogxK

U2 - 10.1038/sj.onc.1204594

DO - 10.1038/sj.onc.1204594

M3 - Article

C2 - 11607814

AN - SCOPUS:0035839867

VL - 20

SP - 5623

EP - 5637

JO - Oncogene

JF - Oncogene

SN - 0950-9232

IS - 40 REV. ISS. 4

ER -